18:49 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample and mouse studies suggest inhibiting IL-22 could help treat KRAS-mutant lung cancer. In KRAS-mutant lung adenocarcinoma patients, high tumor levels of the IL-22 receptor IL22RA1 were associated with poor recurrence-free...
21:15 , May 17, 2018 |  BC Extra  |  Preclinical News

Inhibiting IL-22 could treat KRAS-mutant lung cancer

A study published in Cancer Immunology Research from scientists at the University of Texas MD Anderson Cancer Center suggests inhibiting IL-22 could help treat KRAS-mutant lung cancer. High levels of IL-22 and IL-22-positive cells in primary...
23:07 , May 18, 2017 |  BC Innovations  |  Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
22:23 , Nov 3, 2016 |  BC Innovations  |  Translation in Brief

The I’s have it

A Science study has revealed that anti-inflammatory drugs targeting tumor necrosis factor α (TNFα) work in part by downregulating interleukin-22 receptor subunit alpha 2 (IL22RA2; IL-22BP) to increase IL-22 activity. The findings not only suggest...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased efficacy....
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD1A; interleukin-17 (IL-17); IL-22

Dermatology INDICATION: Dermatitis; psoriasis Mouse and patient sample studies suggest inhibiting CD1A could help treat dermatitis, psoriasis and other inflammatory skin diseases. In a mouse model of poison ivy-induced dermatitis, transgenic expression of human CD1A increased skin...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin 4 (IL-4); IL-10; IL-22; tumor necrosis factor α (TNFα)

Autoimmune disease INDICATION: Psoriasis Cell culture and mouse studies suggest cells engineered to secrete the anti-inflammatory cytokines IL-4 and IL-10 in response to the pro-inflammatory cytokines TNFα and IL-22 could help treat psoriasis. Human embryonic kidney cells...
08:00 , Jan 14, 2016 |  BC Innovations  |  Tools & Techniques

"And" not "or" in psoriasis

Diseases with dynamic, irregular flare-ups like psoriasis may now have a therapeutic platform that can automatically keep up. A Swiss group has designed implantable cells that can detect and treat psoriatic inflammation using cytokine-based Boolean...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-22 (IL-22)

Autoimmune disease INDICATION: Autoimmune TARGET/MARKER/PATHWAY: Interleukin-22 (IL-22) LICENSING STATUS: Patent and licensing status unavailable PUBLICATION DETAILS: Barone, F. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 18, 2015 doi:10.1073/pnas.1503315112 CONTACT: Francesca Barone, University of Birmingham, Birmingham, U.K. e-mail: f.barone@bham.ac.uk...
08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity IL-22; IL-23; IL-24 (MDA7) Mouse studies suggest IL-22 or inhibition of IL-23 and IL-24...